David B. Duggan

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

I. Craig Henderson, Donald A. Berry, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 1.3K citations

Medicine, Oncology, Pharmacology +17

Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup Trial

David B. Duggan, Gina R. Petroni, Jeffrey L. Johnson et al. · Journal of Clinical Oncology · 2003 · 485 citations

Medicine, Oncology, Pharmacology +14

Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342

Eric P. Winer, Donald A. Berry, Susan Woolf et al. · Journal of Clinical Oncology · 2004 · 271 citations · Full text

Medicine, Oncology, Pharmacology +12

Immunochemical similarities between monoclonal antibacterial Waldenstrom's macroglobulins and monoclonal anti-DNA lupus autoantibodies.

Yaakov Naparstek, David B. Duggan, Ami Schattner et al. · The Journal of Experimental Medicine · 1985 · 134 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

Daniel F. Hayes, Hideko Yamauchi, Gloria Broadwater et al. · PubMed · 2001 · 96 citations

Medicine, Cancer Biology, Oncology +17